title: A novel improved therapy strategy for diabetic nephropathy: targeting AGEs.
abstract: Diabetic nephropathy (DN), is a disorder that causes significant morbidity and mortality. Studies on the pathological mechanisms of DN reveal that advanced glycation end products (AGEs) play an important role in the pathogenesis of DN through interacting with receptors for advanced glycation end products (RAGE), which activate a series of intracellular signaling pathways. AGEs and RAGE have therefore been considered to be two potential key targets. Although multiple studies have been made for anti-DN therapy against AGEs or RAGE, the results have been disappointing due to poor effectiveness or to side effects in clinical practice. In this hypothesis article, we propose a novel treatment based on a dual-target approach. A kind of multi-functional intelligent nanoparticle is constructed, which has a core-shell nanoparticle structure to load the dual-target drugs (AGEs inhibitors and RAGE inhibitors), and has a functional "RAGE analog" to be used as "bait" to catch AGEs and target them to the kidney. Owing to its advantages of having a dual-target, synergistic effect and high efficiency, the proposition may have potential applications in DN therapy.
authors.affiliation: Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
authors.forename: Xuemei
authors.initials: X
authors.lastname: Zhou
authors.forename: Bochu
authors.initials: B
authors.lastname: Wang
authors.forename: Liancai
authors.initials: L
authors.lastname: Zhu
authors.forename: Shilei
authors.initials: S
authors.lastname: Hao
mesh_terms: D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D016503:Drug Delivery Systems; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans
chemical_list: D017127:Glycation End Products, Advanced